Labroots is excited to announce the 15th Annual Event in the Clinical Diagnostics & Research Virtual Event Series on November 13th, 2024! This event will again bring together clinicians, researchers, medical experts, and professionals to elevate collaboration, advance clinical diagnostics, research, and medicine, and ensure that patient care continues improving with the latest scientific breakthroughs.
This year’s event promises to be a comprehensive and engaging forum where thousands of attendees will discuss the continuous progress in laboratory testing and patient care. With new technologies and treatments, staying updated on regulatory processes is crucial to ensure patient safety and proper practices.
This years tracks include:
Clinical Diagnostics and Methods
- Liquid Biopsy and Circulating Biomarkers: Non-invasive diagnostic tools that detect cancer and genetic mutations through blood samples.
- CRISPR-Based Diagnostics: Gene-editing technology applied to diagnostics for rapid, specific detection of diseases.
- Point-of-Care Testing (POCT): Diagnostic testing performed at or near the patient, providing immediate results and reducing reliance on centralized labs.
- Digital Labs and Remote Diagnostics: Virtual diagnostic tools and remote data processing that improve lab efficiency and allow for off-site diagnostic capabilities.
- Metabolic Biomarkers: Identifying key metabolites in the body that indicate specific health conditions, including metabolic disorders, to guide diagnosis and treatment.
Translational Research: From Bench to Bedside and Back Again
- Early Phase Clinical Trials to evaluate the safety of new therapeutic strategies in patients
- Late Phase Clinical Trials to test for therapeutic efficacy in a controlled clinical setting
- Research on clinical outcomes to access implementation into clinical practice
- The value of correlative studies to validate scientific and clinical progress
- Regulatory considerations and challenges
Epidemiology
- CRISPR-Based Diagnostics in Infectious Diseases: The use of CRISPR technology to identify infectious diseases rapidly and support public health surveillance.
- Microbiome Analysis in Epidemiology: The study of microbial communities to understand the role they play in disease outbreaks and public health.
Opioid Crisis
- Monitoring Opioid Use: Advanced diagnostic techniques, including molecular assays and liquid biopsies, to track patient compliance and drug metabolism.
- Non-Opioid Alternative Treatments: Exploring alternatives to opioid-based treatments, such as biologics and other therapeutic interventions.
- Biomarker Discovery for Pain Management: Identifying novel biomarkers to guide personalized pain management therapies.
- TDM (Therapeutic Drug Monitoring) for Biologics: Ensuring optimal dosages of biologic treatments to improve outcomes in pain management.
- Liquid Biopsy for Drug Monitoring: Utilizing liquid biopsy to non-invasively monitor the presence of drugs and metabolites in patients.
Regulatory
- Regulatory Implications of Molecular Diagnostics: Examining the regulatory challenges and approvals associated with introducing molecular diagnostics into clinical practice.
- Proficiency Testing for HgA1c: Ensuring accuracy and consistency in HbA1c testing through regulated proficiency testing standards.
- Impact of PAMA: Assessing how the Protecting Access to Medicare Act affects lab test pricing and reimbursement, especially for molecular diagnostics.
- Biomarker Validation: The process of confirming that a biomarker is a reliable indicator of a specific biological or disease state, essential for regulatory approval.
Clinical Lab Value
- Liquid Biopsy in Clinical Practice: How liquid biopsy contributes to improving diagnostic precision, offering non-invasive and real-time monitoring for diseases.
- Molecular Diagnostics: Advances in genomics, proteomics, and next-generation sequencing that enhance the capabilities of clinical labs for personalized medicine.
- The application of AI and ML for diagnostics: Implementing ML applications for workflow efficiency.
This event is accepting abstract submissions for on-demand educational talks on relevant topics. For more information, please contact our Senior Scientific Editor, Sarah Hoffman (sarah.hoffman@labroots.com).
Call for Posters — Virtual poster sessions offer the opportunity to present data to a global audience via a PDF poster and video summary, and discuss results with interested colleagues through email. Plan now to have your poster included in the 2024 Clinical Diagnostics Virtual Event. Submission is free. Submit your abstract here.
Our virtual conference allows you to participate in a global setting with no travel or cost to you. The event will remain open for 2 years from the date of the live event, and the webinars will be available for unlimited on-demand viewing. This virtual conference also offers increased reach for the global clinical diagnostics and research community with a high degree of interaction through live-streaming video and chat sessions.
Continuing Education
Labroots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this event, you can earn 1 Continuing Education credit per presentation for a maximum of 30 credits.
Labroots is a proud partner of Chati, a virtual event platform that allows for the hosting of engaging and interactive virtual and hybrid events, catering to businesses of any vertical or size.
Connect with us!
When you attend the event remember to use the hashtag #LRclinical to follow the conversation and connect with other members of the global Clinical & Molecular Dx community!
Follow @Diagnostics_LR on Twitter and @ClinicalandMolecularDiagnostics.LR on Facebook to connect with our specialist Clinical & Molecular Dx Writers and stay up to date with the latest Trending News in Clinical & Molecular Dx.
Now, you can also join our Clinical & Molecular Dx Interest Group on LinkedIn to connect with us, and the wider professional community!